Text Size

The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00728871
First received: August 1, 2008
Last updated: August 5, 2008
Last verified: August 2008
History of Changes
  Purpose

A. To investigate the relationship between serum titer of anti-HPV16 antibody and clinicopathological factors of cervical cancer patients.

B. To investigate that if the serum titer of anti-HPV16 antibody could be a prognostic factor in the cervical cancer patients.

C. To investigate the serum titer of anti-HPV16 antibody in HPV16-infected populations with various disease status such as infection only, precancerous lesion, and early and advanced cervical cancer.


Condition Intervention
Cervical Cancer
Cervical Intraepithelial Neoplasia
 Procedure: peripheral blood isolation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and CIN Patients and Their Prognosis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • overall survival [ Time Frame: from CS operation to close ] [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: December 2005
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: peripheral blood isolation
    To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. cervical intrapeithelial neoplasm
  2. Cervical cancer

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00728871

Contacts
Contact: Chi-An Chen, MD 886-2-2312-3456 ext 5166 cachen@ha.mc.ntu.edu.tw

Locations
China, Taiwan
Natioanal Taiwan Univ. Hospital Recruiting
Taipei, Taiwan, China, 100
Contact: Chi-An Chen, MD     886-2-2312-3456 ext 5166     cachen@ha.mc.ntu.edu.tw    
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: Chi-An Chen, MD National Taiwan University Hospital
Study Chair: Chi-An Chen, MD National Taiwan Univ. Hosp.
  More Information

No publications provided

Responsible Party: Chi-An Chen/Professor, National Taiwan Unviersity Hospital
ClinicalTrials.gov Identifier: NCT00728871     History of Changes
Other Study ID Numbers: 9461700838
Study First Received: August 1, 2008
Last Updated: August 5, 2008
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
cervical cancer, HPV, immunity

Additional relevant MeSH terms:
Neoplasms
Uterine Cervical Neoplasms
Cervical Intraepithelial Neoplasia
Carcinoma in Situ
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
 Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on May 19, 2013